All Stories

  1. Metformin protects retinal ganglion cells in a preclinical model of retinal ischemia/reperfusion injury and stabilizes visual field in diabetic patients with glaucoma
  2. Topical WIN 55,212-2 Confers Long-Term Intraocular-Pressure-Independent Neuroprotection in the DBA/2J Mouse Model of Glaucoma
  3. Comparing eptinezumab with onabotulinumtoxinA in the treatment of chronic migraine: a real-world evidence study
  4. Pharmacoutilization data-driven AI-assisted diagnosis algorithm to improve the pharmacological treatment of pain and agitation in patients suffering from severe dementia
  5. Efficacy and safety of mAbs anti-CGRP/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol
  6. Multi-center Translational Trial of Remote Ischemic Conditioning in Acute Ischemic Stroke (TRICS BASIC)
  7. Clinical and Market Analysis of NanoBEO: A Public-Worth, Innovative Therapy for Behavioral and Psychological Symptoms of Dementia (BPSD)—Emerging Evidence and Its Implications for a Health Technology Assessment (HTA) and Decision-Making in National Hea...
  8. The Antidepressant Drug Amitriptyline Affects Human SH-SY5Y Neuroblastoma Cell Proliferation and Modulates Autophagy
  9. Brain Ischemic Tolerance Triggered by Preconditioning Involves Modulation of Tumor Necrosis Factor-α-Stimulated Gene 6 (TSG-6) in Mice Subjected to Transient Middle Cerebral Artery Occlusion
  10. Efficacy of therapeutic intervention with NanoBEO to manage agitation and pain in patients suffering from severe dementia: a pilot clinical trial
  11. Hericenone C attenuates the second phase of formalin-induced nociceptive behavior by suppressing the accumulation of CD11c-positive cells in the paw epidermis via phosphorylated P65
  12. Basic, Translational, and Clinical Research on Dementia
  13. Role of Spinal Cholecystokinin Octapeptide, Nociceptin/Orphanin FQ, and Hemokinin-1 in Diabetic Allodynia
  14. Motor behavior induced by bergamot essential oil in experimental tasks is differentially modulated by pretreatment with metabotropic glutamate receptor 2/3 or 5 antagonists
  15. Epigenetic and nanotechnology alliance to fight stroke-induced brain damage
  16. Zeaxanthin exerts anti-inflammatory effects in vitro and provides significant neuroprotection in mice subjected to transient middle cerebral artery occlusion
  17. Exploitation of Autophagy Inducers in the Management of Dementia: A Systematic Review
  18. Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establi...
  19. Decoding metabolic signatures in Alzheimer’s disease: a mitochondrial perspective
  20. Effect of genotype on individual response to the pharmacological treatment of glaucoma: a systematic review and meta-analysis
  21. Scopolamine-Induced Memory Impairment in Mice: Effects of PEA-OXA on Memory Retrieval and Hippocampal LTP
  22. Neuroprotective Effect of a Nutritional Supplement Containing Spearmint Extract, Forskolin, Homotaurine and Group B Vitamins in a Mouse Model of Transient Ocular Hypertension
  23. Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
  24. Efficacy of Essential Oils in Relieving Cancer Pain: A Systematic Review and Meta-Analysis
  25. Characterization of the Involvement of Tumour Necrosis Factor (TNF)-α-Stimulated Gene 6 (TSG-6) in Ischemic Brain Injury Caused by Middle Cerebral Artery Occlusion in Mouse
  26. Harmonization of sensorimotor deficit assessment in a registered multicentre pre-clinical randomized controlled trial using two models of ischemic stroke
  27. Tumor Necrosis Factor (TNF)-α-Stimulated Gene 6 (TSG-6): A Promising Immunomodulatory Target in Acute Neurodegenerative Diseases
  28. 2-pentadecyl-2-oxazoline prevents cognitive and social behaviour impairments in the Amyloid β-induced Alzheimer-like mice model: Bring the α2 adrenergic receptor back into play
  29. Focus On Zavegepant: The First Intranasal Third-Generation Gepant
  30. NAbiximols Clinical Translation To the treatment of Pain and Agitation In Severe Dementia (NACTOPAISD): Clinical trial protocol
  31. Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence
  32. Analgesic Characteristics of NanoBEO Released by an Airless Dispenser for the Control of Agitation in Severe Dementia
  33. Transgenic Mice for the Translational Study of Neuropathic Pain and Dystonia
  34. Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
  35. Dementia therapeutics and cognitive rehabilitation
  36. Pharmacotechnological Advances for Clinical Translation of Essential Oils for the Treatment of Pain and Agitation in Severe Dementia
  37. Targeting Neuroplasticity for the Management of Pain and Agitation in Alzheimer’s Disease via Bergamot Nanotherapy
  38. Homo-AMPA in the periaqueductal grey modulates pain and rostral ventromedial medulla activity in diabetic neuropathic mice
  39. Requirements for Translation in Clinical Trials of Aromatherapy: The Case of the Essential Oil of Bergamot (BEO) for Management of Agitation in Severe Dementia
  40. CB1R, CB2R and TRPV1 expression and modulation in in vivo, animal glaucoma models: A systematic review
  41. Pain and agitation treatment in severe dementia patients: The need for Italian Mobilization–Observation–Behavior–Intensity–Dementia (I-MOBID2) pain scale translation, adaptation and validation with psychometric testing
  42. Translational Value of the Transdermal Administration of Bergamot Essential Oil and of Its Fractions
  43. PEA-OXA ameliorates allodynia, neuropsychiatric and adipose tissue remodeling induced by social isolation
  44. Pharmacological Treatment of Pain and Agitation in Severe Dementia and Responsiveness to Change of the Italian Mobilization–Observation–Behavior–Intensity–Dementia (I-MOBID2) Pain Scale: Study Protocol
  45. Antispasmodic Effect of Bergamot Essential Oil on Rat Isolated Gut Tissues
  46. Ischemic Preconditioning Modulates the Peripheral Innate Immune System to Promote Anti-Inflammatory and Protective Responses in Mice Subjected to Focal Cerebral Ischemia
  47. Real world considerations for newly approved CGRP receptor antagonists in migraine care
  48. ROBOCOP (ROBOtic Care of Poststroke Pain): Study Protocol for a Randomized Trial to Assess Robot-Assisted Functional and Motor Recovery and Impact on Poststroke Pain Development
  49. Dementia and COVID-19: A Case Report and Literature Review on Pain Management
  50. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence
  51. Preclinical Characterization of Antinociceptive Effect of Bergamot Essential Oil and of Its Fractions for Rational Translation in Complementary Therapy
  52. Aromatherapy in Stroke Patients: Is it Time to Begin?
  53. New trends in pharmacological control of neuropsychiatric symptoms of dementia
  54. Exploitation of Thermal Sensitivity and Hyperalgesia in a Mouse Model of Dystonia
  55. Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
  56. Bergamot rehabilitation AgaINst agitation in dementia (BRAINAID): Study protocol for a randomized, double‐blind, placebo‐controlled trial to assess the efficacy of furocoumarin‐free bergamot loaded in a nanotechnology‐based delive...
  57. Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
  58. Editorial: “Novel Pain Therapeutics: From Basic Research to Clinical Translation and Rehabilitation”
  59. Systemic administration of sunflower oil exerts neuroprotection in a mouse model of transient focal cerebral ischaemia
  60. Development and Translation of NanoBEO, a Nanotechnology-Based Delivery System of Bergamot Essential Oil Deprived of Furocumarins, in the Control of Agitation in Severe Dementia
  61. Efficacy of Essential Oils in Pain: A Systematic Review and Meta-Analysis of Preclinical Evidence
  62. Effect of Gabapentin in a Neuropathic Pain Model in Mice Overexpressing Human Wild-Type or Human Mutated Torsin A
  63. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
  64. Opioids in Post-stroke Pain: A Systematic Review and Meta-Analysis
  65. Multicentre translational Trial of Remote Ischaemic Conditioning in Acute Ischaemic Stroke (TRICS): protocol of multicentre, parallel group, randomised, preclinical trial in female and male rat and mouse from the Italian Stroke Organization (ISO) Basic...
  66. Contribution of Histamine to Nociceptive Behaviors Induced by Intrathecally Administered Cholecystokinin-8
  67. Natural Products: Evidence for Neuroprotection to Be Exploited in Glaucoma
  68. Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia
  69. Effects of the autophagy modulators d-limonene and chloroquine on vimentin levels in SH-SY5Y cells
  70. Pain Assessment and Treatment in Dementia at the Time of Coronavirus Disease COVID-19
  71. Behavioral Effects of Continuously Administered Bergamot Essential Oil on Mice With Partial Sciatic Nerve Ligation
  72. Modulation of Cerebral Store-operated Calcium Entry-regulatory Factor (SARAF) and Peripheral Orai1 Following Focal Cerebral Ischemia and Preconditioning in Mice
  73. Pharmacokinetic Interactions between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance
  74. Effects of Aging on Formalin-Induced Pain Behavior and Analgesic Activity of Gabapentin in C57BL/6 Mice
  75. Role of 5-HT1A Receptor in the Anxiolytic-Relaxant Effects of Bergamot Essential Oil in Rodent
  76. The Role of Autophagy in Glaucomatous Optic Neuropathy
  77. Pattern of triptans use: a retrospective prescription study in Calabria, Italy
  78. Brain networks reorganization and functional disability in glaucoma
  79. Effects of caloric restriction on retinal aging and neurodegeneration
  80. Evidence on the neuroprotective properties of brimonidine in glaucoma
  81. Impact of nutraceuticals on glaucoma: A systematic review
  82. Preface
  83. Preface
  84. Azithromycin Affords Neuroprotection in Rat Undergone Transient Focal Cerebral Ischemia
  85. Aging Brain: In Search of Better Neurotherapeutics
  86. Neuropharmacological Properties of the Essential Oil of Bergamot for the Clinical Management of Pain-Related BPSDs
  87. Anxiolytic-Like Effects of Bergamot Essential Oil Are Insensitive to Flumazenil in Rats
  88. Neuropharmacology of the Neuropsychiatric Symptoms of Dementia and Role of Pain: Essential Oil of Bergamot as a Novel Therapeutic Approach
  89. New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
  90. The tricyclic antidepressant clomipramine inhibits neuronal autophagic flux
  91. Diabetic retinopathy and age-related macular degeneration: a survey of pharmacoutilization and cost in Calabria, Italy
  92. Eptinezumab for the treatment of migraine
  93. Possible involvement of the peripheral Mu-opioid system in antinociception induced by bergamot essential oil to allodynia after peripheral nerve injury
  94. Rapamycin and fasting sustain autophagy response activated by ischemia/reperfusion injury and promote retinal ganglion cell survival
  95. Antinociceptive effect of inhalation of the essential oil of bergamot in mice
  96. Glaucoma and Alzheimer Disease: One Age-Related Neurodegenerative Disease of the Brain
  97. Glaucoma: In Search of Better Neurotherapeutics
  98. Paradigm Shift to Neuroimmunomodulation for Translational Neuroprotection in Stroke
  99. On the Role of Store-Operated Calcium Entry in Acute and Chronic Neurodegenerative Diseases
  100. Neuroprotective agents in the management of glaucoma
  101. Early LC3 lipidation induced by d -limonene does not rely on mTOR inhibition, ERK activation and ROS production and it is associated with reduced clonogenic capacity of SH-SY5Y neuroblastoma cells
  102. Evidence for accuracy of pain assessment and painkillers utilization in neuropsychiatric symptoms of dementia in Calabria region, Italy
  103. Excitatory and inhibitory amino acid neurotransmitters in stroke: from neurotoxicity to ischemic tolerance
  104. Bergamot Essential Oil Attenuates Anxiety-Like Behaviour in Rats
  105. Opioids Resistance in Chronic Pain Management
  106. Aromatherapy and Aromatic Plants for the Treatment of Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Clinical Evidence and Possible Mechanisms
  107. The need for better access to pain treatment: learning from drug consumption trends in the USA
  108. Poly(ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against ischemic stroke in mice
  109. Retinal ganglion cell death in glaucoma: Exploring the role of neuroinflammation
  110. New strategies for neuroprotection in glaucoma, a disease that affects the central nervous system
  111. Neuroprotective Properties of a Macrolide Antibiotic in a Mouse Model of Middle Cerebral Artery Occlusion: Characterization of the Immunomodulatory Effects and Validation of the Efficacy of Intravenous Administration
  112. Involvement of spinal glutamate in nociceptive behavior induced by intrathecal administration of hemokinin-1 in mice
  113. Drug repurposing for immune modulation in acute ischemic stroke
  114. Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition towards M2 phenotype
  115. Activation of RXR/PPARγ underlies neuroprotection by bexarotene in ischemic stroke
  116. Aromatherapy
  117. Rational modulation of the innate immune system for neuroprotection in ischemic stroke
  118. Links among glaucoma, neurodegenerative, and vascular diseases of the central nervous system
  119. Natural compounds and retinal ganglion cell neuroprotection
  120. Autophagy dysregulation and the fate of retinal ganglion cells in glaucomatous optic neuropathy
  121. Drug repurposing and beyond: the fundamental role of pharmacology
  122. Effect of plantar subcutaneous administration of bergamot essential oil and linalool on formalin-induced nociceptive behavior in mice
  123. Exploitation of Cytotoxicity of Some Essential Oils for Translation in Cancer Therapy
  124. Preface: New Trends in Basic and Clinical Research of Glaucoma: A Neurodegenerative Disease of the Visual System Part A
  125. Preface: New Trends in Basic and Clinical Research of Glaucoma:A Neurodegenerative Disease of the Visual System Part B
  126. Spinal Autophagy is Differently Modulated in Distinct Mouse Models of Neuropathic Pain
  127. Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia
  128. Role of D-Limonene in Autophagy Induced by Bergamot Essential Oil in SH-SY5Y Neuroblastoma Cells
  129. Early reperfusion injury is associated to MMP2 and IL-1β elevation in cortical neurons of rats subjected to middle cerebral artery occlusion
  130. Inflammation in stroke
  131. The Essential Oil of Bergamot Stimulates Reactive Oxygen Species Production in Human Polymorphonuclear Leukocytes
  132. Implication of limonene and linalyl acetate in cytotoxicity induced by bergamot essential oil in human neuroblastoma cells
  133. Impairment of Neuronal Glutamate Uptake and Modulation of the Glutamate Transporter GLT-1 Induced by Retinal Ischemia
  134. In search of new targets for retinal neuroprotection: is there a role for autophagy?
  135. Brain involvement in glaucoma: advanced neuroimaging for understanding and monitoring a new target for therapy
  136. Peripherally injected linalool and bergamot essential oil attenuate mechanical allodynia via inhibiting spinal ERK phosphorylation
  137. Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception
  138. The involvement of the spinal release of glutamate and nitric oxide in peripheral noxious stimulation-induced pain-related behaviors—Study in mouse spinal microdialysis
  139. Death in pain: peripheral nerve injury and spinal neurodegenerative mechanisms
  140. Understanding anomalous adaptation in chronic pain for successful development of disease modifying drugs
  141. Neuroprotection by leptin in a rat model of permanent cerebral ischemia: effects on STAT3 phosphorylation in discrete cells of the brain
  142. Calpain-mediated cleavage of Beclin-1 and autophagy deregulation following retinal ischemic injury in vivo
  143. IkappaB-alpha expression following transient focal cerebral ischemia is modulated by nitric oxide
  144. Dermorphin tetrapeptide analogs as potent and long-lasting analgesics with pharmacological profiles distinct from morphine
  145. Autophagy impairment in a mouse model of neuropathic pain
  146. Intraplantar injection of bergamot essential oil induces peripheral antinociception mediated by opioid mechanism
  147. Neuropharmacology of the essential oil of bergamot
  148. Identification of distinct cellular pools of interleukin-1β during the evolution of the neuroinflammatory response induced by transient middle cerebral artery occlusion in the brain of rat
  149. Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat
  150. Cell signaling pathways in the mechanisms of neuroprotection afforded by bergamot essential oil against NMDA-induced cell death in vitro
  151. Chapter 28 Identification of Novel Pharmacological Targets to Minimize Excitotoxic Retinal Damage
  152. Chapter 25 Oxidative Stress in Stroke Pathophysiology
  153. Chapter 27 Prevention of Glutamate Accumulation and Upregulation of Phospho‐Akt may Account for Neuroprotection Afforded by Bergamot Essential Oil against Brain Injury Induced by Focal Cerebral Ischemia in Rat
  154. Chapter 17 (–)‐Linalool Attenuates Allodynia in Neuropathic Pain Induced by Spinal Nerve Ligation in C57/Bl6 Mice
  155. Preface
  156. Chapter 18 Intraplantar Injection Of Bergamot Essential Oil Into The Mouse Hindpaw
  157. Post-ischemic brain damage: pathophysiology and role of inflammatory mediators
  158. Post-ischemic brain damage: in search of novel neurotherapeutics
  159. Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death
  160. Modulation of pro-survival and death-associated pathways under retinal ischemia/reperfusion: effects of NMDA receptor blockade
  161. Exploitation of the HIV-1 coat glycoprotein, gp120, in neurodegenerative studies in vivo
  162. Brain regional and cellular localization of gelatinase activity in rat that have undergone transient middle cerebral artery occlusion
  163. Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
  164. 17β-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
  165. Preface
  166. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
  167. Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17β-estradiol
  168. Involvement of the Endocannabinoid System in Retinal Damage after High Intraocular Pressure–Induced Ischemia in Rats
  169. Identification of Transglutaminase 3 Splicing Isoforms
  170. Extracellular signal-regulated kinase (ERK) and nitric oxide synthase mediate intrathecal morphine-induced nociceptive behavior
  171. The essential oil of bergamot enhances the levels of amino acid neurotransmitters in the hippocampus of rat: Implication of monoterpene hydrocarbons
  172. Neuroinflammation in neuronal degeneration and repair
  173. Early Upregulation of Matrix Metalloproteinases Following Reperfusion Triggers Neuroinflammatory Mediators in Brain Ischemia in Rat
  174. Evidence to Implicate Early Modulation of Interleukin‐1β Expression in the Neuroprotection Afforded by 17β‐Estradiol in Male Rats Undergone Transient Middle Cerebral Artery Occlusion
  175. Evidence Implicating Matrix Metalloproteinases in the Mechanism Underlying Accumulation of IL‐1β and Neuronal Apoptosis in the Neocortex of HIV/gp120‐Exposed Rats
  176. Neuroprotective Effect of Nitroglycerin in a Rodent Model of Ischemic Stroke: Evaluation of Bcl‐2 Expression
  177. Preface
  178. Retinal Damage Caused by High Intraocular Pressure–Induced Transient Ischemia is Prevented by Coenzyme Q10 in Rat
  179. Evidence that Nitric Oxide Is Involved in the Control of Electrocortical Arousal
  180. Outcomes of a pharmacoepidemiological survey on the antibiotic treatment of uncomplicated acute cystitis in community☆
  181. The crucial role of neuronal plasticity in pain and cell death
  182. 17β-Estradiol Protects SH-SY5Y Cells Against HIV-1 gp120-Induced Cell Death: Evidence for a Role of Estrogen Receptors
  183. Editorial
  184. 17β-Estradiol Reduces Neuronal Apoptosis Induced by HIV-1 gp120 in the Neocortex of Rat
  185. Neurochemical Evidence to Implicate Elevated Glutamate in the Mechanisms of High Intraocular Pressure (IOP)-induced Retinal Ganglion Cell Death in Rat
  186. From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens
  187. Neuroprotection by the caspase-1 inhibitor Ac-YVAD-(acyloxy)mk in experimental neuroAIDS is independent from IL-1β generation
  188. Estradiol reduces cytochrome c translocation and minimizes hippocampal damage caused by transient global ischemia in rat
  189. Transglutaminase 5 is acetylated at the N-terminal end
  190. Enhanced anandamide degradation is associated with neuronal apoptosis induced by the HIV-1 coat glycoprotein gp120 in the rat neocortex
  191. p73-alpha is capable of inducing scotin and ER stress
  192. A Novel Recessive Connexin 31 (GJB3) Mutation in a Case of Erythrokeratodermia Variabilis
  193. Involvement of a Glutamatergic Mechanism in δ-Dendrotoxin-Induced Hippocampal Neuronal Cell Loss in the Rat
  194. Inducible nitric oxide synthase is involved in the mechanisms of cocaine enhanced neuronal apoptosis induced by HIV-1 gp120 in theneocortex of rat
  195. Neurobiological mediators of neuronal apoptosis in experimental neuroAIDS
  196. Apoptosis in the Mechanisms of Neuronal Plasticity in the Developing Visual System
  197. Calabria: sun, sand, and cell death
  198. Excitotoxic Mechanisms of Apoptosis in the Mammalian Visual System Following Monocular Visual Deprivation
  199. Cholesterol-dependent modulation of the toxicity of HIV-1 coat protein gp120 in human neuroblastoma cells
  200. Abnormal Expression of Neuronal Nitric Oxide Synthase Triggers Limbic Seizures and Hippocampal Damage in Rat
  201. HIV-1 Coat Glycoprotein gp120 Induces Apoptosis in Rat Brain Neocortex by Deranging the Arachidonate Cascade in Favor of Prostanoids
  202. HIV-1 coat protein gp120 stimulates interleukin-1β secretion from human neuroblastoma cells: evidence for a role in the mechanism of cell death
  203. Evidence that the HIV-1 coat protein gp120 causes neuronal apoptosis in the neocortex of rat via a mechanism involving CXCR4 chemokine receptor
  204. Functional role of inducible nitric oxide synthase on mouse colonic motility
  205. Evidence that increases of mitochondrial immunoreactive IL-1β by HIV-1 gp120 implicatein situcleavage of pro-IL-1β in the neocortex of rat
  206. CXCR4-activated astrocyte glutamate release via TNFα: amplification by microglia triggers neurotoxicity
  207. Apoptosis in the Dorsal Lateral Geniculate Nucleus after Monocular Deprivation Involves Glutamate Signaling, NO Production, and PARP Activation
  208. Effects of α-dendrotoxin and dendrotoxin K on extracellular excitatory amino acids and on electroencephalograph spectral power in the hippocampus of anaesthetised rats
  209. Apoptosis Induced by gp120 in the Neocortex of Rat Involves Enhanced Expression of Cyclooxygenase Type 2 and Is Prevented by NMDA Receptor Antagonists and by the 21-Aminosteroid U-74389G
  210. Systemic administration of cocaine, given alone or in combination with sensory stimuli, differentially affects l-arginine-nitric oxide metabolism in discrete regions of the brain of rat
  211. Involvement of interleukin-1β in the mechanism of human immunodeficiency virus type 1 (HIV-1) recombinant protein gp120-induced apoptosis in the neocortex of rat
  212. Conference
  213. Paraquat: A Useful Tool for thein vivoStudy of Mechanisms of Neuronal Cell Death
  214. The HIV Envelope Protein gp120 in the Nervous System
  215. Intrahippocampal injection of paraquat produces apoptotic cell death which is prevented by the lazaroid U74389G, in rats
  216. HIV-1 gp120-Induced Apoptosis in the Rat Neocortex Involves Enhanced Expression of Cyclo-oxygenase Type 2 (COX-2)
  217. Systemic Administration of Nω-Nitro-l-Arginine Methyl Ester and Indomethacin Reduces the Elevation of Brain PGE2Content and Prevents Seizures and Hippocampal Damage Evoked by LiCl and Tacrine in Rat
  218. The effect of hydroxylation of linoleoyl amides on their cannabinomimetic properties
  219. Seizures and Hippocampal Damage Produced by Dendrotoxin-K in Rats Is Prevented by the 21-Aminosteroid U-74389G
  220. N-Methyl-d-aspartate (NMDA) and non-NMDA glutamate receptor antagonists protect from apoptosis induced in the lateral geniculate nucleus of rabbits exposed to the dark
  221. Conference
  222. The human immunodeficiency virus type 1 (HIV-1) glycoprotein gp120 reduces the expression of neuronal nitric oxide synthase in the hippocampus but not in the cerebral cortex and medial septal nucleus of rat
  223. Nω-nitro-L-arginine methyl ester prevents apoptosis induced in the lateral geniculate nucleus by light deprivation in adult rabbit
  224. N-methyl-d-aspartate and nonn-methyl-d-aspartate receptors mediate seizures and CA1 hippocampal damage induced by dendrotoxin-K in rats
  225. Intracerebral injection of human immunodeficiency virus type 1 coat protein gp120 differentially affects the expression of nerve growth factor and nitric oxide synthase in the hippocampus of rat.
  226. Systemic administration of lithium chloride and tacrine but not kainic acid augments citrulline content of rat brain
  227. Possible modulation of auditory middle latency responses by nitric oxide in the inferior colliculus of anaesthetized rats
  228. HIV-1 gp120 Produces DNA Fragmentation in the Cerebral Cortex of Rat
  229. Lack of Involvement of Nitric Oxide in the Mechanisms of Seizures and Hippocampal Damage Produced by Kainate and Ouabain in Rats
  230. Does the HIV-1 coat protein gp120 produce brain damage?
  231. Intracerebral injection of human immunodeficiency virus type 1 coat glycoprotein GP120 does not produce neurodegeneration in rats
  232. Neurodegeneration Produced by Intrahippocampal Injection of Paraquat is Reduced by Systemic Administration of the 21-Aminosteroid U74389F in Rats
  233. Hippocampal damage produced in rats by α-dendrotoxin—a selective K+ channel blocker—involves non-NMDA receptor activation
  234. Tetanus toxin as a neurobiological tool to study mechanisms of neuronal cell death in the mammalian brain
  235. Lithium and Tacrine Increase the Expression of Nitric Oxide Synthase mRNA in the Hippocampus of Rat
  236. Persistent muscarinic excitation in guinea-pig olfactory cortex neurons: Involvement of a slow post-stimulus afterdepolarizing current
  237. HIV gp120 Glycoprotein Stimulates the Inducible Isoform of NO Synthase in Human Cultured Astrocytoma Cells
  238. Systemic administration of lithium chloride and tacrine increases nitric oxide synthase activity in the hippocampus of rats
  239. Inhibition by Nω-nitro-L-arginine methyl ester of the electrocortical arousal response in rats
  240. Antagonists of N-methyl-D-aspartate receptors block seizures induced by putrescine in the deep prepiriform cortex
  241. Altered Sensitivity of ?2-Adrenoceptors in the Brain during Aging in Rats
  242. Glutamate transmission is involved in the mechanisms of neuronal degeneration produced by intrahippocampal tetanus toxin in rats
  243. Production of Limbic Motor Seizures and Brain Damage by Systemic and Intracerebral Injections of Paraquat in Rats
  244. Neurotoxic Effects Induced by Intracerebral and Systemic Injection of Paraquat in Rats
  245. Metabotropic (glutamate) receptor agonists induce a post-stimulus afterdepolarization in guinea-pig olfactory cortex neurones in vitro
  246. Role of nitric oxide in the pathophysiology of epilepsy and brain damage in rats
  247. Production of seizures and brain damage in rats by α-dendrotoxin, a selective K+ channel blocker
  248. Tacrine-induced seizures and brain damage in LiCl-treated rats can be prevented by Nω-nitro-L-arginine methyl ester
  249. Epileptogenic effects of skin extracts from the Australian frog Pseudophryne coriacea after intracerebral microinfusion in rats
  250. Muscarinic receptor activation induces a prolonged post-stimulus afterdepolarization with a conductance decrease in guinea-pig olfactory cortex neurones in vitro
  251. High vulnerability of dentate granule cells to the neuropathological effects induced by intrahippocampal injection of tetanus toxin
  252. Muscarinic inhibition of excitatory neurotransmission in guinea-pig olfactory cortex slices: Weak antagonism by M3-muscarinic receptor antagonists
  253. Hippocampal damage produced by tetanus toxin in rats can be prevented by lesioning CA1 pyramidal cell excitatory afferents
  254. Characteristics of tetanus toxin and its exploitation in neurodegenerative studies
  255. Prevention by the NMDA receptor antagonist, MK801 of neuronal loss produced by tetanus toxin in the rat hippocampus
  256. Different profile of electrocortical power spectrum changes after micro-infusion into the locus coeruleus of selective agonists at various opioid receptor subtypes in rats
  257. Carbachol-induced suppression of the surface N-wave in guinea-pig olfactory cortex slices: Weak antagonism by M3-selective muscarinic antagonists, HHSiD and p-F-HHSiD
  258. Behavioural and neuropathological effects produced by tetanus toxin injected into the hippocampus of rats
  259. Hippocampal damage produced by tetanus toxin in rats can be prevented by lesioning excitatory afferents to CA1 pyramidal cell layer
  260. Muscarinic suppression of the evoked N-wave by oxotremorine-M-recorded in the guinea-pig olfactory cortex slice
  261. Tetanus toxin produces neuronal loss and a reduction in GABAA but not GABAB binding sites in rat hippocampus
  262. Age-dependent ECoG spectrum power alterations are reduced by phosphatidylserine in rats
  263. Inhibition by pertussis toxin of the soporific effects induced by stimulation of dopamine D2, autoreceptors in the ventral tegmental area in rats
  264. Effects of pertussis toxin on the behavioural and ECoG spectrum changes induced by clonidine and yohimbine after their microinfusion into the locus coeruleus
  265. Microinfusion of clonidine and yohimbine into locus coeruleus alters EEG power spectrum: effects of aging and reversal by phosphatidylserine
  266. Dopamine D-2 receptors in the ventral tegmental area mediate behavioural and electrocortical sleep of dopaminergic drugs in rats
  267. Ventral tegmental area: site through which dopamine D2-receptor agonists evoke behavioural and electrocortical sleep in rats
  268. Behavioural and ECoG spectrum power effects after intraventricular injection of drugs altering dopaminergic transmission in rats
  269. Behavioural and electrocortical changes induced by muscimol in rats withdrawn from chronic treatment with diazepam
  270. Behavioural and electrocortical spectrum power effects of growth hormone releasing factor in rats
  271. Electrocortical spectrum power effects of different classes of neuroleptics in rats
  272. Behavioural and spectrum power effects of opioid peptides in chicks
  273. Behavioural and Electrocortical Spectrum Power Changes After Intraventricular Injection of Patulin in Rats
  274. Evidence that behavioural and electrocortical sleep induced by guanfacine is due to stimulation of α2-adrenoceptors